Full-Time
Biotechnology firm specializing in genetic testing
$111.9k - $139.9k/yr
Senior
Company Historically Provides H1B Sponsorship
Remote in USA
Candidates must be based in the United States.
Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera also offers tests for family planning and prenatal screening, including the Panorama NIPT, which has conducted over 2 million tests. The company generates revenue through testing kits and services, often reimbursed by insurance, and provides genetic counseling for personalized patient support.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Austin, Texas
Founded
2004
Help us improve and share your feedback! Did you find this helpful?
Flexible medical plans
Investment options
Time off
Workplace perks
DnB Asset Management AS invests $235,000 in Natera, Inc. (NASDAQ:NTRA).
AUSTIN, Texas - (BUSINESS WIRE) - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025.
Last week, Natera (NasdaqGS:NTRA) announced a strategic expansion of its Board of Directors with the appointment of Monica Bertagnolli.
Natera launches HEROES trial for breast cancer treatment.
Lantheus competes with other companies in the medical and pharmaceutical industries, such as ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.